FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092562585> ?p ?o ?g. }

• W2092562585 endingPage "282" @default.
• W2092562585 startingPage "275" @default.
• W2092562585 abstract "Tolsultazolamide, a novel carbonic anhydrase inhibitor, is designed for the prophylaxis and treatment of acute mountain sickness. The aim of this study was to investigate the pharmacokinetics, tissue distribution, and excretion characteristics of tolsultazolamide and the sex difference in pharmacokinetics in rats.For pharmacokinetic study, rats were intravenously injected tolsultazolamide at 1 and 2 mg/kg or orally administered tolsultazolamide at 20, 40, or 80 mg/kg) in a pharmacokinetic study. The concentrations of tolsultazolamide in plasma were determined with high-performance liquid chromatography, with a liquid-liquid extraction. For tissue distribution study, tolsultazolamide (80 mg/kg) was orally administered to overnight fasted rats (six per group and three per sex). Samples were collected from the brain, heart, lung, liver, spleen, muscle, kidney, stomach, fat, intestines, pancreas and sexual gland. For excretion study, tolsultazolamide (40 mg/kg) was orally administered to 6 rats (three per sex). The urine, feces, and bile samples were collected at 24, 48, and 72 h.After its intravenous administration, tolsultazolamide was rapidly eliminated from the plasma, with T1/2 of about 60-90 min. The AUC0-t and the initial concentration (C0) values were proportional to the intravenous doses. After its oral administration, tolsultazolamide showed dose-independent pharmacokinetic characteristics, with Tmax and T1/2 of approximately 2 h and 5-7 h, respectively, and good oral absolute bioavailability of about 60%. Tolsultazolamide was distributed widely in various tissues. The highest tolsultazolamide levels were detected in the stomach, intestine, spleen, lung, and kidney. Total excretion of unchanged tolsultazolamide in the urine, feces, and bile was less than 2%. The Cmax and AUC of tolsultazolamide were significantly higher in female rats than those in male rats. Clearance and volume of distribution were greater in male rats than those in female rats. The oral absolute bioavailability was also significantly different between female rats (about 83%) and male rats (about 37%).Tolsultazolamide was well absorbed and widely distributed in the rat, and very little of the unchanged form was excreted. Sex had a significant effect on the pharmacokinetics of tolsultazolamide." @default.
• W2092562585 created "2016-06-24" @default.
• W2092562585 creator A5011144900 @default.
• W2092562585 creator A5021091060 @default.
• W2092562585 creator A5036866849 @default.
• W2092562585 creator A5041400868 @default.
• W2092562585 creator A5059639262 @default.
• W2092562585 creator A5073753623 @default.
• W2092562585 creator A5084762460 @default.
• W2092562585 date "2013-12-16" @default.
• W2092562585 modified "2023-10-04" @default.
• W2092562585 title "Bioavailability, tissue distribution, and excretion characteristics of the novel carbonic anhydrase inhibitor tolsultazolamide in rats" @default.
• W2092562585 cites W1922599451 @default.
• W2092562585 cites W1972246626 @default.
• W2092562585 cites W1977898022 @default.
• W2092562585 cites W1978599196 @default.
• W2092562585 cites W1981843848 @default.
• W2092562585 cites W2003923450 @default.
• W2092562585 cites W2006419993 @default.
• W2092562585 cites W2017331060 @default.
• W2092562585 cites W2052085090 @default.
• W2092562585 cites W2067718960 @default.
• W2092562585 cites W2072420784 @default.
• W2092562585 cites W2084851157 @default.
• W2092562585 cites W2089188895 @default.
• W2092562585 cites W2100914124 @default.
• W2092562585 cites W2104336384 @default.
• W2092562585 cites W2105397662 @default.
• W2092562585 cites W2116092110 @default.
• W2092562585 cites W2132215049 @default.
• W2092562585 cites W2134201523 @default.
• W2092562585 cites W2149056662 @default.
• W2092562585 cites W4251188701 @default.
• W2092562585 doi "https://doi.org/10.1038/aps.2013.146" @default.
• W2092562585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4651221" @default.
• W2092562585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24335840" @default.
• W2092562585 hasPublicationYear "2013" @default.
• W2092562585 type Work @default.
• W2092562585 sameAs 2092562585 @default.
• W2092562585 citedByCount "5" @default.
• W2092562585 countsByYear W20925625852015 @default.
• W2092562585 countsByYear W20925625852017 @default.
• W2092562585 countsByYear W20925625852018 @default.
• W2092562585 countsByYear W20925625852021 @default.
• W2092562585 crossrefType "journal-article" @default.
• W2092562585 hasAuthorship W2092562585A5011144900 @default.
• W2092562585 hasAuthorship W2092562585A5021091060 @default.
• W2092562585 hasAuthorship W2092562585A5036866849 @default.
• W2092562585 hasAuthorship W2092562585A5041400868 @default.
• W2092562585 hasAuthorship W2092562585A5059639262 @default.
• W2092562585 hasAuthorship W2092562585A5073753623 @default.
• W2092562585 hasAuthorship W2092562585A5084762460 @default.
• W2092562585 hasBestOaLocation W20925625851 @default.
• W2092562585 hasConcept C10146269 @default.
• W2092562585 hasConcept C110121322 @default.
• W2092562585 hasConcept C112705442 @default.
• W2092562585 hasConcept C126322002 @default.
• W2092562585 hasConcept C134018914 @default.
• W2092562585 hasConcept C134306372 @default.
• W2092562585 hasConcept C181389837 @default.
• W2092562585 hasConcept C185592680 @default.
• W2092562585 hasConcept C2776280935 @default.
• W2092562585 hasConcept C2777056448 @default.
• W2092562585 hasConcept C2777882243 @default.
• W2092562585 hasConcept C2779422922 @default.
• W2092562585 hasConcept C2780026642 @default.
• W2092562585 hasConcept C2780091579 @default.
• W2092562585 hasConcept C2780931953 @default.
• W2092562585 hasConcept C33923547 @default.
• W2092562585 hasConcept C71924100 @default.
• W2092562585 hasConcept C98274493 @default.
• W2092562585 hasConceptScore W2092562585C10146269 @default.
• W2092562585 hasConceptScore W2092562585C110121322 @default.
• W2092562585 hasConceptScore W2092562585C112705442 @default.
• W2092562585 hasConceptScore W2092562585C126322002 @default.
• W2092562585 hasConceptScore W2092562585C134018914 @default.
• W2092562585 hasConceptScore W2092562585C134306372 @default.
• W2092562585 hasConceptScore W2092562585C181389837 @default.
• W2092562585 hasConceptScore W2092562585C185592680 @default.
• W2092562585 hasConceptScore W2092562585C2776280935 @default.
• W2092562585 hasConceptScore W2092562585C2777056448 @default.
• W2092562585 hasConceptScore W2092562585C2777882243 @default.
• W2092562585 hasConceptScore W2092562585C2779422922 @default.
• W2092562585 hasConceptScore W2092562585C2780026642 @default.
• W2092562585 hasConceptScore W2092562585C2780091579 @default.
• W2092562585 hasConceptScore W2092562585C2780931953 @default.
• W2092562585 hasConceptScore W2092562585C33923547 @default.
• W2092562585 hasConceptScore W2092562585C71924100 @default.
• W2092562585 hasConceptScore W2092562585C98274493 @default.
• W2092562585 hasIssue "2" @default.
• W2092562585 hasLocation W20925625851 @default.
• W2092562585 hasLocation W20925625852 @default.
• W2092562585 hasLocation W20925625853 @default.
• W2092562585 hasLocation W20925625854 @default.
• W2092562585 hasOpenAccess W2092562585 @default.
• W2092562585 hasPrimaryLocation W20925625851 @default.
• W2092562585 hasRelatedWork W1555144605 @default.
• W2092562585 hasRelatedWork W1964074490 @default.

• next